Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers

Tanasković, Slobodan; Radak, Djordje; Aleksić, Nikola; Čalija, Branko; Maravić-Stojković, Vera; Nenezić, Dragoslav; Ilijevski, Nenad; Popov, Petar; Vučurević, Goran; Babić, Srdjan; Matić, Predrag; Gajin, Predrag; Vasić, Dragan; Rančić, Zoran

doi:10.1016/j.jvs.2017.09.054

Cited by 15 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Nevertheless, elevated baseline hs-CRP levels were independently associated with increased ischemic stroke risk in a meta-analysis summarizing results of 12 studies, which included more than 2000 patients 29 and also predicted early restenosis after carotid endarterectomy. 30 Pentraxin-3. Pentraxin-3 (PTX3) is another acute phase protein that has been reported associated with the presence of atherosclerotic plaques 31 and elevated levels of PTX3 were also found in patients with plaque instability undergoing carotid stenting.…”

Section: Biomarker Descriptionsmentioning

confidence: 99%

Review of serum biomarkers in carotid atherosclerosis

Martinez

Martorell

Riambau

2020

Journal of Vascular Surgery

View full text Add to dashboard Cite

Background: Carotid artery atherosclerotic stenosis is a preventable major cause of stroke, but there is still a need for definition of high-risk plaque in asymptomatic patients who might benefit from interventional therapies. Several image markers are recommended to characterize unstable plaques. The measurement of serum biomarkers is a promising method to assist in decision making, but the lack of robust evidence in the carotid environment burdens their potential as a standard of care. The goal of this review was to offer an updated state-of-the-art study of available serum biomarkers with clinical implications, with focus on those that may predict carotid symptom development. Methods: The Cochrane Library and MEDLINE databases were searched (all until September 2018) for studies on carotid plaque and serum biomarkers of atherosclerosis. Nonhuman, basic science, and histology studies were excluded, focusing on clinical studies. Selected abstracts were screened to include the most relevant articles on atherosclerotic plaque presence, progression, instability or symptom development. Results: Some well-established biomarkers for coronary disease are not relevant to carotid atherosclerosis and other inflammatory biomarkers, lipids, interleukins, homocysteine, and adipokines may be useful in quantifying carotid disease-related risk. Some serum biomarkers combined with image features may assist vascular specialists in selecting patients at high risk for stroke and in need of intervention. Conclusions: Prospective studies applying a combination of biomarkers are essential to prove clinical usefulness.

show abstract

Section: Biomarker Descriptionsmentioning

confidence: 99%

Review of serum biomarkers in carotid atherosclerosis

Martinez

Martorell

Riambau

2020

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…Patients with end-stage renal disease can develop endothelial dysfunction through several mechanisms, including elevated low-density lipoprotein, decreased adiponectin levels, and decreased clearance of proinflammatory and oxidative substances (94). Inflammation also plays a role in early carotid restenosis after CEA, as demonstrated by the elevated risk of restenosis associated with a rise in the high-sensitivity CRP level before CEA and increased fibrinogen 48 h after surgery (95,96).…”

Section: Risk Factors For Restenosis After Cea and Casmentioning

confidence: 99%

The management of carotid restenosis: a comprehensive review

Stilo¹,

Montelione²,

Calandrelli³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Carotid artery stenosis (CS) is a major medical problem affecting approximately 10% of the general population 80 years or older and causes stroke in approximately 10% of all ischemic events. In patients with symptomatic, moderate-to-severe CS, carotid endarterectomy (CEA) and carotid angioplasty and stenting (CAS), has been used to lower the risk of stroke. In primary CS, CEA was found to be superior to best medical therapy (BMT) according to 3 large randomized controlled trials (RCT). Following CEA and CAS, restenosis remains an unsolved problem involving a large number of patients as the current treatment recommendations are not as clear as those for primary stenosis. Several studies have evaluated the risk of restenosis, reporting an incidence ranging from 5% to 22% after CEA and an in-stent restenosis (ISR) rate ranging from 2.7% to 33%. Treatment and optimal management of this disease process, however, is a matter of ongoing debate, and, given the dearth of level 1evidence for the management of these conditions, the relevant guidelines lack clarity. Moreover, the incidence rates of stroke and complications in patients with carotid stenosis are derived from studies that did not use contemporary techniques and materials.Rapidly changing guidelines, updated techniques, and materials, and modern medical treatments make actual incidence rates barely comparable to previous ones. For these reasons, RCTs are critical for determining whether these patients should be treated with more aggressive treatments additional to BMT and identifying those patients indicated for surgical or endovascular treatments. This review summarizes the current evidence and controversies concerning the risks, causes, current treatment options, and prognoses in patients with restenosis after CEA or CAS.

show abstract

“…Furthermore, it will be critical to develop scalable methods to learn clinical concepts that can be translated across disparate healthcare systems. Extraction of actionable EMD insights has already been demonstrated for neurologic disorders, such as psychoses and severe mental illness (Kadra et al, 2015) as well as diabetic (McAdam-Marx et al, 2011) and cardiovascular (Tanaskovic et al, 2018) pathologies, all of which possess potential aging pathology causes (Kennedy et al, 2014;Franceschi et al, 2018;van Gastel et al, 2018a).…”

Section: Electronic Medical Data File Analyticsmentioning

confidence: 99%

High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases

et al. 2019

View full text Add to dashboard Cite

large volumes of high-dimensionality data (e.g., transcriptomics, proteomics, metabolomics), it is now imperative that effective tools to appreciate this highly nuanced data are developed. Being able to appreciate the subtleties of high-dimensionality data will allow molecular pharmacologists to develop the most effective multidimensional therapeutics with effectively engineered efficacy profiles.

show abstract

Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers

Cited by 15 publications

References 47 publications

Review of serum biomarkers in carotid atherosclerosis

Review of serum biomarkers in carotid atherosclerosis

The management of carotid restenosis: a comprehensive review

High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases

Contact Info

Product

Resources

About